Literature DB >> 21767349

Is the PANSS used correctly? a systematic review.

Michael Obermeier1, Rebecca Schennach-Wolff, Sebastian Meyer, Hans-Jürgen Möller, Michael Riedel, Daniela Krause, Florian Seemüller.   

Abstract

BACKGROUND: The PANSS (Positive and Negative Syndrome Scale) is one of the most important rating instruments for patients with schizophrenia. Nevertheless, there is a long and ongoing debate in the psychiatric community regarding its mathematical properties.All 30 items range from 1 to 7 leading to a minimum total score of 30, implying that the PANSS is an interval scale. For such interval scales straightforward calculation of relative changes is not appropriate. To calculate outcome criteria based on a percent change as, e.g., the widely accepted response criterion, the scale has to be transformed into a ratio scale beforehand. Recent publications have already pointed out the pitfall that ignoring the scale level (interval vs. ratio scale) leads to a set of mathematical problems, potentially resulting in erroneous results concerning the efficacy of the treatment.
METHODS: A Pubmed search based on the PRISMA statement of the highest-ranked psychiatric journals (search terms "PANSS" and "response") was carried out. All articles containing percent changes were included and methods of percent change calculation were analysed.
RESULTS: This systematic literature research shows that the majority of authors (62%) actually appear to use incorrect calculations. In most instances the method of calculation was not described in the manuscript.
CONCLUSIONS: These alarming results underline the need for standardized procedures for PANSS calculations.

Entities:  

Mesh:

Year:  2011        PMID: 21767349      PMCID: PMC3146924          DOI: 10.1186/1471-244X-11-113

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  45 in total

1.  Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.

Authors:  Daniel Sechter; Joseph Peuskens; Odile Fleurot; Werner Rein; Yves Lecrubier
Journal:  Neuropsychopharmacology       Date:  2002-12       Impact factor: 7.853

2.  A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms.

Authors:  Malcolm Peet; David F Horrobin
Journal:  J Psychiatr Res       Date:  2002 Jan-Feb       Impact factor: 4.791

3.  Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Authors:  Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Jeffrey A Lieberman; Leslie Citrome; Brian Sheitman; Miranda Chakos; Joseph P McEvoy
Journal:  J Clin Psychiatry       Date:  2002-10       Impact factor: 4.384

4.  Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups.

Authors:  Robin A Emsley; Mimi C Roberts; Solomon Rataemane; Janus Pretorius; Piet P Oosthuizen; Jadri Turner; Dana J H Niehaus; Natasha Keyter; Dan J Stein
Journal:  J Clin Psychiatry       Date:  2002-01       Impact factor: 4.384

5.  A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.

Authors:  Alan Breier; Karena Meehan; Martin Birkett; Stacy David; Iris Ferchland; Virginia Sutton; Cindy C Taylor; Rebecca Palmer; Martin Dossenbach; Geri Kiesler; Shlomo Brook; Padraig Wright
Journal:  Arch Gen Psychiatry       Date:  2002-05

6.  A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia.

Authors:  D L Copolov; C G Link; B Kowalcyk
Journal:  Psychol Med       Date:  2000-01       Impact factor: 7.723

7.  Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.

Authors:  Hsien-Yuan Lane; Yue-Cune Chang; Yiao-Cheung Cheng; Guang-Chyi Liu; Xing-Ru Lin; Wen-Ho Chang
Journal:  J Clin Psychiatry       Date:  2003-03       Impact factor: 4.384

8.  The effect of antipsychotic treatment on Theory of Mind.

Authors:  Romina Mizrahi; Michele Korostil; Sergio E Starkstein; Robert B Zipursky; Shitij Kapur
Journal:  Psychol Med       Date:  2006-11-09       Impact factor: 7.723

9.  Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

Authors:  W Wolfgang Fleischhacker; Mariëlle Eerdekens; Keith Karcher; Gary Remington; Pierre-Michel Llorca; Wlodzimierz Chrzanowski; Stephen Martin; Ola Gefvert
Journal:  J Clin Psychiatry       Date:  2003-10       Impact factor: 4.384

10.  Risperidone in the treatment of schizotypal personality disorder.

Authors:  Harold W Koenigsberg; Diedre Reynolds; Marianne Goodman; Antonia S New; Vivian Mitropoulou; Robert L Trestman; Jeremy Silverman; Larry J Siever
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more
  26 in total

1.  Attachment Style and Insight in Schizophrenia: a Cross-Sectional Study.

Authors:  Gustavo França; Erika Laranjeira; Fabio Silva; Lília Monteiro; Ana Maria Moreira; Serafim Carvalho
Journal:  Psychiatr Q       Date:  2020-03

2.  The lack of impact of quality-of-life measures in schizophrenia: a shared responsibility?

Authors:  Laurent Boyer; Pascal Auquier
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

Review 3.  Psychometric evaluation of the negative syndrome of schizophrenia.

Authors:  Maria Paz Garcia-Portilla; Leticia Garcia-Alvarez; Pilar A Saiz; Susana Al-Halabi; Maria Teresa Bobes-Bascaran; Maria Teresa Bascaran; José Muñiz; Julio Bobes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

4.  Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses.

Authors:  Ariana E Anderson; Stephen Marder; Steven P Reise; Adam Savitz; Giacomo Salvadore; Dong Jing Fu; Qingqin Li; Ibrahim Turkoz; Carol Han; Robert M Bilder
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

5.  Converting positive and negative symptom scores between PANSS and SAPS/SANS.

Authors:  Theo G M van Erp; Adrian Preda; Dana Nguyen; Lawrence Faziola; Jessica Turner; Juan Bustillo; Aysenil Belger; Kelvin O Lim; Sarah McEwen; James Voyvodic; Daniel H Mathalon; Judith Ford; Steven G Potkin
Journal:  Schizophr Res       Date:  2013-12-11       Impact factor: 4.939

6.  Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features.

Authors:  Marco Calabrò; Stefano Porcelli; Concetta Crisafulli; Sheng-Min Wang; Soo-Jung Lee; Changsu Han; Ashwin A Patkar; Prakash S Masand; Diego Albani; Ilaria Raimondi; Gianluigi Forloni; Sofia Bin; Carlotta Cristalli; Vilma Mantovani; Chi-Un Pae; Alessandro Serretti
Journal:  J Mol Neurosci       Date:  2017-11-21       Impact factor: 3.444

7.  Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.

Authors:  Ina Giegling; Beatrice Balzarro; Stefano Porcelli; Martin Schäfer; Annette M Hartmann; Marion Friedl; Bettina Konte; Philipp Krämer; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Alessandro Serretti; Dan Rujescu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-08-15       Impact factor: 5.270

Review 8.  Quantifying clinical relevance in the treatment of schizophrenia.

Authors:  Christoph U Correll; Taishiro Kishimoto; Jimmi Nielsen; John M Kane
Journal:  Clin Ther       Date:  2011-12       Impact factor: 3.393

9.  Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.

Authors:  Matea Nikolac Perkovic; Gordana Nedic Erjavec; Maja Zivkovic; Marina Sagud; Suzana Uzun; Alma Mihaljevic-Peles; Oliver Kozumplik; Dorotea Muck-Seler; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2014-03-05       Impact factor: 4.530

Review 10.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Authors:  Oliver D Howes; Rob McCutcheon; Ofer Agid; Andrea de Bartolomeis; Nico J M van Beveren; Michael L Birnbaum; Michael A P Bloomfield; Rodrigo A Bressan; Robert W Buchanan; William T Carpenter; David J Castle; Leslie Citrome; Zafiris J Daskalakis; Michael Davidson; Richard J Drake; Serdar Dursun; Bjørn H Ebdrup; Helio Elkis; Peter Falkai; W Wolfgang Fleischacker; Ary Gadelha; Fiona Gaughran; Birte Y Glenthøj; Ariel Graff-Guerrero; Jaime E C Hallak; William G Honer; James Kennedy; Bruce J Kinon; Stephen M Lawrie; Jimmy Lee; F Markus Leweke; James H MacCabe; Carolyn B McNabb; Herbert Meltzer; Hans-Jürgen Möller; Shinchiro Nakajima; Christos Pantelis; Tiago Reis Marques; Gary Remington; Susan L Rossell; Bruce R Russell; Cynthia O Siu; Takefumi Suzuki; Iris E Sommer; David Taylor; Neil Thomas; Alp Üçok; Daniel Umbricht; James T R Walters; John Kane; Christoph U Correll
Journal:  Am J Psychiatry       Date:  2016-12-06       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.